Entera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 10 2020 - 8:30AM
Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of
orally delivered large molecule therapeutics, announced that
members of its management team will participate virtually in the
H.C. Wainwright Global Investment Conference on Tuesday,
September 15, 2020 at 3:00 p.m. EDT.
To access a live webcast of the fireside chat on
the “Investor Relations” page of Entera’s website, please click
here. A replay of the webcast will be archived on Entera’s website
for approximately 45 days following the presentation.
About Entera Bio
Entera is a leader in the development of orally
delivered macromolecule therapeutics for use in areas with
significant unmet medical need where adoption of injectable
therapies is limited due to cost, convenience and compliance
challenges for patients. The Company’s proprietary, oral drug
delivery technology is designed to address the technical challenges
of poor absorption, high variability, and the inability to deliver
large molecules to the targeted location in the body through the
use of a synthetic absorption enhancer to facilitate the absorption
of large molecules, and protease inhibitors to prevent enzymatic
degradation and support delivery to targeted tissues. The Company’s
most advanced product candidates, EB613 for the treatment of
osteoporosis and EB612 for the treatment of hypoparathyroidism are
in Phase 2 clinical development. Entera also licenses its
technology to biopharmaceutical companies for use with their
proprietary compounds and, to date, has established a collaboration
with Amgen Inc. For more information on Entera Bio, visit
www.enterabio.com.
Contact:
Jonathan Lieber, CFO
Tel: +001 617-362-3579
jon@enterabio.com
Entera Bio (NASDAQ:ENTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entera Bio (NASDAQ:ENTX)
Historical Stock Chart
From Apr 2023 to Apr 2024